Email Artikel ini Terap Obat Kombinasi Asma Bronkial Pada Pasien Dewasa
Abstrak
ABSTRAK
Asma bronkial merupakan penyakit inflamasi kronik pada saluran pernapasan yang menyebabkan hiperaktivitas yang ditandai dengan adanya peradangan bronkial kronis. Agen anti-inflamasi utama yang digunakan untuk pengobatan asma bronkial adalah Inhaled Corticosteroid (ICS), stabilisator sel mast, dan penghambat autakoid. Saat ini, kortikosteroid merupakan agen paling efektif untuk pengobatan asma bronkial. Namun, penggunaan kortikosteroid secara sistemik terbatas karena kemungkinan efek sampingnya. Oleh karena itu, penggunaan ICS pada umumnya dikombinasikan dengan Long Acting Beta Agonis (LABA). Berbagai uji klinis telah menunjukkan sinergi antara terapi LABA dan ICS yang menghasilkan kontrol gejala yang efektif dalam pencegahan eksaserbasi asma. Review ini dibuat dengan tujuan menganalisis hasil terapi obat kombinasi asma bronkial pada pasien dewasa.
ABSTRACT
Bronchial asthma is a chronic inflammatory disease of the respiratory tract that causes hyperactivity characterized by chronic bronchial inflammation. The main anti-inflammatory agents used for the treatment of bronchial asthma are Inhaled Corticosteroids (ICS), mast cell stabilizers, and autacoid inhibitors. Currently, corticosteroids are the most effective agents for the treatment of bronchial asthma. However, systemic use of corticosteroids is limited because of their possible side effects. Therefore, the use of ICS is generally combined with Long Acting Beta Agonists (LABA). Various clinical trials have demonstrated the synergy between LABA therapy and ICS resulting in effective symptom control in the prevention of asthma exacerbations. This review was created with the aim of analyzing the results of combination drug therapy for bronchial asthma in adult patients.
Teks Lengkap:
PDFReferensi
Altshuler, D. M., Gibbs, R. A., et al. 2010. Integrating common and rare genetic variation in diverse human populations. Nature, 467: 52-58.
Anselmo, M. 2011. Pediatric asthma controller therapy. Paediatr Drugs, (13): 11-17.
Billington, C.K., Penn, R.B., Hall, I.P. (2016). β2 Agonists, in: Page, C.P., Barnes, P.J. (Eds.), Pharmacology and Therapeutics of Asthma and COPD, Handbook of Experimental Pharmacology. Springer International Publishing, Cham: 23–40.
Burke, W., Fesinmeyer, M., et al. 2013. Family history as a predictor of asthma risk. Am J Prev Med, 24: 160-169.
Dipiro, J. T., Talbert, R. L., et al. 2011. Pharmacotherapy: A Pathophysiologic Approach 8th Edition. New York: McGraw Hill.
Harvey, R.A., Champe, P.C. (2016). Farmakologi Ulasan Bergambar, 4th ed. Jakarta: EGC.
Hawkins, G. A., Tantisira, K., et al. 2016. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma casecontrol study. Am J Respir Crit Care Med, 174(10): 1101-1109.
Israel, E., Chinchilli, V. M., et al. 2014. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet, 364: 1505-512.
Kasrin, D., Pratiwi, L., & Rizkifani, S. 2022. Penggolongan Obat Berdasarkan Peresepan Obat Asma Di Instalasi Rawat Jalan RSUD Dr Agoesdjam Ketapang. Journal Syifa Sciences and Clinical Research, 4(1): 179-189.
Keinan, A. & Clark, A. G. 2012. Recent explosive human population growth has resulted in an excess of rare genetic variants. Science, 336: 740-743.
Kerstjens, H. A. M., Engel, et al. 2012. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med, 367: 1198-1207.
Lambrecht, B. N. & Hammad, H. 2015. The immunology of asthma. Immunology of The Lung, (16): 45-50.
Lemanske Jr, R. F., Mauger, D. T., et al. 2010. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med, 362: 975-985.
Lipworth, B. J., Basu, K., et al. 2013. Tailored second-line therapy in asthmatic children with the Arg16 genotype. Clin Sci (Lond), 124: 521-528.
Malmstrom, K., Rodriguez-Gomez, G., et al. 1999. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med, 130: 487-495.
Marth, G., Schuler, G., et al. 2013. Sequence variations in the public human genome data reflect a bottlenecked population history. Proc Natl Acad Sci USA, 100(1): 376-381.
Miller, S. M., & Ortega, V. E. 2013. Pharmacogenetics and the Development of Personalized Approaches for Combination Therapy in Asthma. Curr Allergy Asthma Rep, 13: 443-452.
Murray, J. F., Nadel, J. A., & Broaddus, V. C. 2016. Murray & Nadel’s Textbook of Respiratory Medicine Sixth Edition. United States of America: Elsevier.
National Heart Lung Blood Institute. 2007. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. United States of America: National Heart, Lung, and Blood Institute.
Ortega, V. E., Hawkins, G. A., Peters, S. P., & Bleecker, E. R. 2017. Pharmacogenetics of the beta 2-adrenergic receptor gene. Immunol Allergy Clin North Am, 27: 665-684.
Peters, S. P., Kunselman, S. J., et al. 2010. Tiotropium bromide stepup therapy for adults with uncontrolled asthma. N Engl J Med, 363: 1715-1726.
Poon, A. H., Tantisira, K. G., et al. 2008. Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. Pharmacogenet Genomics, 18: 373-382.
Pratt, W. B., Galigniana, M. D., Harrell, J. M., & DeFranco, D. B. 2014. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal, 16: 857-872.
Profita, M., Gagliardo, R., Di Giorgi, R., Pompeo, F., Gjomarkaj, M., Nicolini, G., Bousquet, J., & Vignola, A. M. 2015. Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy, 60: 323-329.
Roberts, L. 2011. 9 billion? Science, 333(6042): 540-543.
Silverman, E. K., Kwiatkowski, D. J., Sylvia, J. S., et al. 2013. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol, 112: 870-876.
Small, K. M., Brown, K. M., Theiss, C. T., Seman, C. A., Weiss, S. T., Liggett, S. B.. 2003. An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation. Pharmacogenetics, 13: 535-541.
Southworth, T., Kaur, M., Hodgson, L., Facchinetti, F., Villetti, G., Civelli, M., & Singh, D. 2019. Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients. Cytokine, 113(1): 68-73.
Sorkness, C. A., Lemanske Jr, R. F., Mauger, D. T., et al. 2007. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol, 119: 64-72.
Usmani, O. S., Ito, K., Maneechotesuwan, K., Ito, M., Johnson, M., Barnes, P. J., & Adcock, I. M. 2015. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med, 172: 704-712.
Vesell, E. S. 1989. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther, 41: 535-552.
Wechsler, M. E., Castro, M., Lehman, E., Chinchilli, V. M., Sutherland, E. R., Denlinger, L., Lazarus, S. C., Peters, S. P., Israel, E. 2011. Impact of race on asthma treatment failures in the asthma clinical research network. Am J Respir Crit Care Med, 184(11): 1247-1253.
Wirasuta, I. M. A. G., Yustiantara, P. S., & Astuti, N. M. W. 2013. Isu Etik Dalam Penelitian Farmakogenomik. Jakarta: Universitas Yarsi Press.
Yudhawati, R. & Krisdanti, P. A. 2017. Imunopatogenesis Asma. Jurnal Respirasi, 3(1): 26-3.
DOI: https://doi.org/10.24198/farmaka.v21i3.47924
DOI (PDF): https://doi.org/10.24198/farmaka.v21i3.47924.g21461
Refbacks
- Saat ini tidak ada refbacks.
##submission.license.cc.by-nc4.footer##
Sitasi manajer:
Jurnal ini diindeks dalam:
Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Copyright © 2013 Jurnal Farmaka - All Right Reserved